DC Chemicals · Product datasheet

RBN-2397 — Datasheet

CAT. NO. DC31069

Product page and current package options

ParameterValue
Chemical NameRBN-2397
CAS No.2381037-82-5
SynonymsRBN-2397,RBN 2397,RBN2397
FormulaC20H23F6N7O3
M.Wt523.43
SMILESO=C1NN=CC(N[C@H](COCCC(=O)N2CCN(C3N=CC(C(F)(F)F)=CN=3)CC2)C)=C1C(F)(F)F
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

RBN-2397 is a potent, accross species and orally active NAD+ competitive inhibitor of PARP7 (IC50<3 nM). RBN-2397 selectively binds to PARP7 (Kd=0.001 μM) and restores interferon (Type I) signaling. RBN-2397 has the potential for the study of advanced or metastatic solid tumors[1][2].

In Vitro

RBN-2397 (0.0001-100 μM; 24 hours) inhibits cells proliferation with an IC50 value of 20 nM in NCI-H1373 lung cancer cells[2]. RBN-2397 (0.4 nM-1 μM; 24 hours) shows a restoration of type I IFN response by an increase in STAT1 phosphorylation as a dose-dependent manner in NCI-H1373 human lung cancer cells[2]. RBN-2397 (0.0001-1 μM; 24 hours) inhibits cell MARylation in a cell biochemial assay with an EC50 value of 1 nM[2]. Cell Proliferation Assay[2] Cell Line: NCI-H1373 lung cancer cells Concentration: 0.0001 μM; 0.001 μM; 0.001 μM; 0.1 μM; 1 μM; 10 μM; 100 μM Incubation Time: 24 hours Result: Blocked cell proliferation. Western Blot Analysis[2] Cell Line: NCI-H1373 lung cancer cells Concentration: 0.4 nM-1 μM Incubation Time: 24 hours Result: Increased p-STAT1 protein expression.

In Vivo

RBN-2397 (oral administration; 3-100 mg/kg; once daily; 24-32 days) induces tumor-specific adaptive immune memory in CT26 syngeneic model with durable complete responses in CT26 tumor-bearing BALB/c mice[2]. RBN-2397 (oral administration; 3-100 mg/kg; once daily; 32 days) causes complete regressions at the dose 100 mg/kg and exerts a dose-dependent effects on tumor growth at dose levels of ≥30 mg/kg[2]. The half-life (t1/2) of RBN-2397 in vivo is 325 mins[2]. Animal Model: CB17 SCID mice with NCI-H1373 xenografts[2] Dosage: 3 mg/kg, 10mg/kg, 30 mg/kg, 100 mg/kg Administration: Oral administration; once daily; 24-32 days Result: Decreased tumor volume and exerted anti-tumor effects.

References & source

[1]. RBN-2397-Inhibiting PARP7, a Key monoPARP Cancer Dependency

[2]. Melissa Vasbinder, et al. RBN-2397: A First-in-Class PARP7 Inhibitor Targeting a Newly Discovered Cancer Vulnerability in Stress-Signaling Pathways.

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

Cart

Request quotation